Search

Your search keyword '"Martín-Mola, E."' showing total 306 results
Start Over Author "Martín-Mola, E."
306 results on '"Martín-Mola, E."'

3. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis

Author

Farahmand, P., Marin, F., Hawkins, F., Möricke, R., Ringe, J. D., Glüer, C.-C., Papaioannou, N., Minisola, S., Martínez, G., Nolla, J. M., Niedhart, C., Guañabens, N., Nuti, R., Martín-Mola, E., Thomasius, F., Peña, J., Graeff, C., Kapetanos, G., Petto, H., Gentzel, A., Reisinger, A., and Zysset, P. K.

Published
2013
Full Text
View/download PDF

7. III Actualización del Consenso de la Sociedad Española de Reumatología sobre terapia biológica en la artritis reumatoide

Author

Rodríguez-Valverde, Vicente, Cáliz Cáliz, Rafael, Álvaro-Gracia Álvaro, José M., Marenco de la Fuente, José L., Mulero Mendoza, Juan, Tornero Molina, Jesús, Andréu Sánchez, J.L., Ballina García, F.J., Batlle Gualda, E., Cañete Crespillo, J.D., Carbonell Abelló, J., Carreño Pérez, L., Figueroa Pedrosa, M., Gómez-Reino Carnota, J., González García, T., Laffon Roca, A., Martín Mola, E., Pascual Gómez, E., Sanmartí Sala, R., Salazar Vallinas, J.M., and Valverde García, J.

Published
2006
Full Text
View/download PDF

11. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative

Author

Machado, P, Castrejon, I, Katchamart, W, Koevoets, R, Kuriya, B, Schoels, M, Silva-Fernández, L, Thevissen, K, Vercoutere, W, Villeneuve, E, Aletaha, D, Carmona, L, Landewé, R, van der Heijde, D, Bijlsma, J W J, Bykerk, V, Canhão, H, Catrina, A I, Durez, P, Edwards, C J, Mjaavatten, M D, Leeb, B F, Losada, B, Martín-Mola, E M, Martinez-Osuna, P, Montecucco, C, Müller-Ladner, U, Østergaard, M, Sheane, B, Xavier, R M, Zochling, J, and Bombardier, C

Published
2011
Full Text
View/download PDF

12. AB0030 INCREASED CIRCULATING CD19+CD24HICD38HI REGULATORY B CELLS ARE BIOMARKERS OF RESPONSE TO METHOTREXATE IN EARLY RHEUMATOID ARTHRITIS

Author

Fortea-Gordo, P., primary, Villalba, A., additional, Nuño, L., additional, Santos-Bornez, M. J., additional, Peiteado, D., additional, Monjo, I., additional, Puig-Kröger, A., additional, Sanchez-Mateos, P., additional, Martín-Mola, E., additional, Balsa, A., additional, and Miranda-Carus, M. E., additional

Published
2020
Full Text
View/download PDF

13. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative

Author

Visser, K, Katchamart, W, Loza, E, Martinez-Lopez, J A, Salliot, C, Trudeau, J, Bombardier, C, Carmona, L, van der Heijde, D, Bijlsma, J W J, Boumpas, D T, Canhao, H, Edwards, C J, Hamuryudan, V, Kvien, T K, Leeb, B F, Martín-Mola, E M, Mielants, H., Müller-Ladner, U, Murphy, G, Østergaard, M, Pereira, I A, Ramos-Remus, C, Valentini, G, Zochling, J, and Dougados, M

Published
2009
Full Text
View/download PDF

21. EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Author

Zhang, W, Doherty, M, Leeb, B F, Alekseeva, L, Arden, N K, Bijlsma, J W, Dinçer, F, Dziedzic, K, Häuselmann, H J, Herrero-Beaumont, G, Kaklamanis, P, Lohmander, S, Maheu, E, Martín-Mola, E, Pavelka, K, Punzi, L, Reiter, S, Sautner, J, Smolen, J, Verbruggen, G, and Zimmermann-Górska, I

Published
2007

31. Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity

Author

Plasencia, C., Gerrit Jan Wolbink, Krieckaert, C. L. M., Kneepkens, E. L., Turk, S., Jurado, T., Martínez-Feito, A., Navarro-Compán, V., Bonilla, G., Villalba, A., Peiteado, D., Nuño, L., Martín-Mola, E., Nurmohamed, M. T., Kleij, D., Rispens, T., Pascual-Salcedo, D., Balsa, A., Rheumatology, ICaR - Circulation and metabolism, AII - Inflammatory diseases, and Landsteiner Laboratory

Subjects
musculoskeletal diseases, skin and connective tissue diseases
Abstract

The aim of this study is to compare clinical outcomes, incidence of flares and administered drug reduction between rheumatoid arthritis (RA) patients under TNF inhibitors (TNFi) tapering strategy and RA patients on standard regimen. Two groups of RA patients on TNFi with DAS28

Published
2016

33. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis

Author

González-Álvaro I, Martínez-Fernández C, Dorantes-Calderón B, García-Vicuña R, Hernández-Cruz B, Herrero-Ambrosio A, Ibarra-Barrueta O, Martín-Mola E, Monte-Boquet E, Morell-Baladrón A, Sanmartí R, Sanz-Sanz J, de Toro-Santos FJ, Vela P, Román Ivorra JA, Poveda-Andrés JL, Muñoz-Fernández S, and Spanish Rheumatology Society

Subjects
rheumatoid arthritis, psoriatic arthritis, dose reduction, bDMARD, ankylosing spondylitis, biologics, cDMARD, risk/benefit ratio, optimization
Abstract

Objective. The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Methods. Recommendations were established via consensus by a panel of experts in rheumatology and hospital pharmacy, based on analysis of available scientific evidence obtained from four systematic reviews and on the clinical experience of panellists. The Delphi method was used to evaluate these recommendations, both between panellists and among a wider group of rheumatologists. Results. Previous concepts concerning better management of RA, AS and PsA were reviewed and, more specifically, guidelines for the optimization of biologic therapies used to treat these diseases were formulated. Recommendations were made with the aim of establishing a plan for when and how to taper biologic treatment in patients with these diseases. Conclusion. The recommendations established herein aim not only to provide advice on how to improve the risk: benefit ratio and efficiency of such treatments, but also to reduce variability in daily clinical practice in the use of biologic therapies for rheumatic diseases.

Published
2015

36. SAT0157 Tocilizumab Serum Trough Levels Correlate with Clinical Activity in Rheumatoid Arthritis

Author

Tornero Marín, C., primary, Plasencia, C., additional, Pascual Salcedo, D., additional, Jurado, T., additional, Paredes, M.B., additional, Monjo, I., additional, Moral, E., additional, Pieren, A., additional, Bonilla Hernán, G., additional, Peiteado, D., additional, Bogas, P., additional, Nuño, L., additional, Villalba Yllan, A., additional, Martín Mola, E., additional, and Balsa Criado, A., additional

Published
2016
Full Text
View/download PDF

37. AB0660 Predictors of Flare after Tapering Anti-TNF Therapy in Patients with Axial Spondyloarthritis

Author

Monjo Henry, I., primary, Plasencia, C., additional, Navarro-Compán, V., additional, Paredes, B., additional, Bonilla, G., additional, Nuño, L., additional, Peiteado, D., additional, Villalba, A., additional, Pascual-Salcedo, D., additional, Ramiro, S., additional, de Miguel, E., additional, Martín-Mola, E., additional, and Balsa, A., additional

Published
2016
Full Text
View/download PDF

41. Novel Approach to Estimate Osteoarthritis Progression: Use of the Reliable Change Index in the Evaluation of Joint Space Loss

Author

Parsons, Camille M., Judge, Andrew, Leyland, Kirsten, Bruyère, Olivier, Petit Dop, Florence, Chapurlat, Roland, Reginster, Jean‐Yves, Edwards, Mark H., Dennison, Elaine M., Cooper, Cyrus, Inskip, Hazel, Christiansen, C., Delmas, P., Genant, H., Zacher, J., Bellamy, N., Speirs, C., Bréart, G., Meyer, O., Gensburger, D., Arlot, M., Roux, J.‐P., Deroisy, R., Sambrook, P., Leeb, B., Verbruggen, A., Bensen, W., Hala, T., Holm‐Bentzen, M., Valter, I., Chevalier, X., Swoboda, B., Adami, S., Kloppenburg, M., Grazuleviciute, E., Badurski, J., Branco, J., Nasonov, E., Navarro, F., Spector, T., Barnsley, L., Hall, S., Jones, G., Klestov, A., March, L., Nash, P., Romas, E., Will, R., Erlacher, L., Leeb, F. B., Resch, H., Rainer, F., Zamani, O., Appelboom, T., Devogelaer, J. P., Kvasz, A., Raeman, F., Verbruggen, A., Beaulieu, A. D., Bensen, W. G., Brown, J., Cividino, A. A., Morin, F., Olszynski, W. P., Raynauld, J. P., Thorne, J. C., Hala, T., Pavelka, K., Alexandersen, P., Hoeck, H. C., Holm‐Bentzen, M., Lundqvist, P., Valter, I., Aim, L., Audouy, P., Beaunier, P., Benhamou, C. L., Berenbaum, F., Chabaud, E., Chalet, D., Chevalier, X., Cohen‐Solal, M., Delbecq, D., Euller‐Ziegler, L., Fardellone, P., Hilliquin, P., Jacquety, E., Jude, N., Lechevalier, D., Mouchet, J. C., Richette, P., Sainte Lorette, E., Schaeverbeke, T., Sebbah, A., Vignot, E., Brabant, T., Burmester, G. R., Grifka, J., Müller, P. E. M., Swoboda, B., Zacher, J., Adami, S., Bianchi, G., Grassi, W., Di Matteo, L., Modena, V., Di Munno, O., Ortolani, S., Punzi, L., Zangari, M., Grazuleviciute, E., Kloppenburg, M., Roorda, L. D., Van Riel, P. L. C. M., Badurski, J., Czerwinski, E., Gorecki, A., Tlustochowicz, W., Branco, J., Canas Da Silva, J., Melo Gomes, J. A., Miranda, L. M., Radulescu, F., Alexeeva, L. I., Orlov‐Morozov, A. V., Pikhlak, E. G., Pilyaev, V. G., Shostak, N. A., Shmidt, E. I., Zagorodniy, N. V., Arboleya Rodríguez, L., Benito Ruiz, P., Chamizo Carmona, E., Collantes Estévez, E., Herrero‐Beaumont, G., Martín Mola, E., Moreno, A., Naranjo Hernández, A., Navarro Sarabia, F., Padrino, J. M., Palacios, C., Rodríguez De La Serna, A., Román Ivorra, J. A., Torrijos, A., Abdulhakim, E., Arden, N., Birrell, F., Donnachie, H., Fraser, W., Keen, R., Sarmiento, R., and Stone, M. D.

Abstract

Osteoarthritis‐related changes in joint space measurements over time are small and sensitive to measurement error. The Reliable Change Index (RCI) determines whether the magnitude of change observed in an individual can be attributed to true change. This study aimed to examine the RCIas a novel approach to estimating osteoarthritis progression. Data were from 167 men and 392 women with knee osteoarthritis (diagnosed using the American College of Rheumatology criteria) randomized to the placebo arm of the 3‐year Strontium Ranelate Efficacy in Knee Osteoarthritis trial (SEKOIA) and assessed annually. The RCIwas used to determine whether the magnitude of change in joint space width (JSW) on radiographs between study years was likely to be true or due to measurement error. Between consecutive years, 57–69% of participants had an apparent decrease (change <0) in JSW, while 31–43% of participants had annual changes indicating improvement in JSW. The RCIidentified JSWdecreases in only 6.0% of patients between baseline and year 1, and in 4.5% of patients between the remaining study years. The apparent increases in JSWwere almost eliminated between baseline and year 1, and between years 1 and 2 only 1.3% of patients had a significant increase, dropping to 0.9% between years 2 and 3. The RCIprovides a method to identify change in JSW, removing many apparent changes that are likely to be due to measurement error. This method appears to be useful for assessing change in JSWfrom radiographs in clinical and research settings.

Published
2019
Full Text
View/download PDF

45. Tratamiento con infliximab (anti-TNF alfa) en pacientes con enfermedad de Still del adulto: Experiencia de dos casos

Author

Bonilla Hernán, Mª G., Cobo Ibáñez, T., Miguel Mendieta, E. de, and Martín-Mola, E.

Subjects
Adult Still´s disease, Enfermedad de Still del adulto, Anti-TNF-alpha treatment, Infliximab, a%2E<%2FFONT>%22">Tratamiento con anti-TNF-a.
Abstract

La enfermedad de Still del adulto es una enfermedad inflamatoria crónica de etiología desconocida. Los antinflamatorios no esteroideos (AINEs) y los glucocorticoides son la base del tratamiento, pero en casos refractarios o cuando la dosis de esteroides es muy elevada es necesario recurrir al tratamiento con fármacos antireumáticos modificadores de la enfermedad (FAME). Ultimamente se ha comenzado a utilizar tratamientos biológicos como alternativa terapéutica a los casos de enfermedad de Still del adulto refractaria al tratamiento convencional. Presentamos nuestra experiencia satisfactoria del tratamiento con infliximab en dos pacientes con esta enfermedad. Adult Still´s disease is a systemic inflammatory disorder of unknown etiolgy. First-line treatment for Still´s disease includes nonsteroidal anti-inflammatory drugs and corticosteroids. In refractory cases o when the dose of corticosteroid is unacceptbly high, other disease modifiying antirheumatic drugs have been used. But recent study showed the efficacy anti-TNF therapy in adult Sill´s disease refractory to conventional therapy We report a favourable response to infliximab in two patients who has proved resistant to conventional therapy.

Published
2004

46. SAT0334 Comparison of Clinical Outcomes between Spondyloarthritis Patients Treated with TNF Inhibitors in Daily Clinical Practise: Tapering versus Standard Therapy: Table 1

Author

Plasencia, C., primary, Wolbink, G., additional, Kneepkens, E., additional, Krieckaert, C., additional, l'Ami, M., additional, Peiteado, D., additional, Nuno, L., additional, Arribas, F., additional, Nurmohamed, M., additional, Martín-Mola, E., additional, Balsa, A., additional, and Pascual-Salcedo, D., additional

Published
2014
Full Text
View/download PDF

49. OP0253 The Early Infliximab Levels Monitoring Can Predict the Developement of Anti-Drug Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab

Author

Chamaida, P.-R., primary, Pascual-Salcedo, D., additional, Bonilla, M., additional, Villalba, A., additional, Lόpez-Casla, M., additional, Peiteado, D., additional, García-Carazo, S., additional, Ramiro, S., additional, Franco, K., additional, Cajigas, D., additional, Martín-Mola, E., additional, and Balsa, A., additional

Published
2014
Full Text
View/download PDF

50. AB0165 A Decreased Frequency of Circulating Follicullar Helper T Cell Counterparts and Plasmablasts in Ankylosing Spondylitis is Restored by TNF Blockers

Author

Bautista-Caro, M.-B., primary, Arroyo-Villa, I., additional, Castillo-Gallego, C., additional, de Miguel, E., additional, Peiteado, D., additional, Plasencia-Rodríguez, C., additional, Villalba, A., additional, Puig-Kröger, A., additional, Martín-Mola, E., additional, and Miranda-Carus, M.-E., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results